TCRT · Alaunos Therapeutics, Inc. · Executive Compensation
$1.74
-0.10 (-5.43%)
At close · Nov 6
Return incl. dividend (before tax)
Q1 2023 earnings call transcript
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.42M
Shares
2.54M
Volume · Nov 6
101.46K
Avg daily vol (3M)
7.43M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Melinda Lackey | Legal & Administration, Corporate Secretary | $430,370 |
| Kevin S. Boyle, Sr. | Former Chief Executive Officer | $392,500 |
| Kevin Boyle | Former Chief Executive Officer | $392,500 |
| Dale Curtis Hogue | Interim Chief Executive Officer | $308,344 |
| Ferdinand Groenewald | Vice President, Finance | $162,304 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Melinda Lackey | SVP, Legal & Administration | $701,737 |
| Drew Deniger | VP, Research and Development | $629,680 |
| Dale Curtis Hogue | Interim Chief Executive Officer | $48,153 |
| Ferdinand Groenewald | Vice President, Finance | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin Boyle | Chief Executive Officer | $1,792,818 |
| Kevin S. Boyle, Sr. | Chief Executive Officer | $1,792,818 |
| Drew Deniger | VP, Research and Development | $949,113 |
| Melinda Lackey | SVP, Legal & Administration | $764,743 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin Boyle | Chief Executive Officer | $4,573,753 |
| Kevin S. Boyle, Sr. | Chief Executive Officer | $4,573,753 |
| Heidi Hagen | Former Interim Chief Executive Officer | $2,730,871 |
| Eleanor de Groot | EVP, Operations | $2,174,017 |
| Jill Buck | Former EVP, GM Gene Therapy | $1,873,742 |
| Laurence James Neil Cooper | Former Chief Executive Officer | $1,531,130 |
| Raffaele Baffa | Chief Medical Officer | $1,034,270 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | Former Chief Executive Officer | $3,007,922 |
| Raffaele Baffa | Chief Medical Officer | $1,673,584 |
| Satyavrat Shukla | Former Chief Financial Officer | $1,252,211 |
| Robert Hadfield | Chief Legal Officer and Secretary | $1,006,811 |
| Eleanor de Groot | EVP, Operations | $935,112 |
| Heidi Hagen | Former Interim Chief Executive Officer | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | Former Chief Executive Officer | $3,317,574 |
| Satyavrat Shukla | Former Chief Financial Officer | $1,822,218 |
| David Mauney | President | $1,448,931 |
| Robert Hadfield | Chief Legal Officer and Secretary | $1,081,822 |
| Kevin G. Lafond | Sr. Vice President – Finance, Chief | $843,123 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | Former Chief Executive Officer | $1,589,239 |
| Robert Hadfield | Chief Legal Officer and Secretary | $836,091 |
| David Mauney | President | $608,756 |
| Kevin G. Lafond | Sr. Vice President – Finance, Chief | $398,998 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Laurence James Neil Cooper | M.D., Ph.D. Chief Executive Officer | $2,894,244 |
| David Mauney | President | $2,297,974 |
| Kevin G. Lafond | Sr. Vice President – Finance, Chief Accounting Officer and Treasurer | $581,224 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Peter Harwin | Board of Directors | Appointed | 2026-10-13 |
| Michael A. Jerman | director | Resigned | 2026-10-13 |
| Jaime W. Vieser | director | Resigned | 2026-10-13 |
| Robert W. Postma | director | Resigned | 2026-10-13 |
| Peter Harwin | director | Appointed | 2026-10-13 |
| Melinda Lackey | Legal and Administrative Officer | Resigned | 2025-07-22 |
| Holger Weis | Chief Executive Officer | Appointed | 2025-07-17 |
| Dale Curtis Hogue | director | Resigned | 2025-07-17 |
| Michael A. Jerman | director | Appointed | 2025-07-17 |
| Dale Curtis Hogue, Jr. | Director | Resigned | 2025-07-02 |
| Holger Weis | Chief Executive Officer | Appointed | 2025-07-02 |
| Dale Curtis Hogue, Jr. | Chief Executive Officer | Resigned | 2025-07-02 |
| Robert Hofmeister, Ph.D. | member of the board of directors | Resigned | 2025-04-18 |
| Ferdinand Groenewald | Vice President, Finance | Appointed | 2024-02-22 |
| Michael Wong | Vice President, Finance | Resigned | 2024-02-22 |
| Dale Curtis Hogue, Jr. | Interim Chief Executive Officer | Appointed | 2024-01-22 |
| Dale Curtis Hogue, Jr. | director | Appointed | 2024-01-02 |
| Kevin S. Boyle, Sr. | board of directors | Resigned | 2023-12-28 |
| Kevin S. Boyle, Sr. | Chief Executive Officer | Terminated | 2023-12-28 |
| Mary Thistle | member of the board of directors | Resigned | 2023-12-22 |
| Drew Deniger | Vice President, Research and Development | Terminated | 2023-11-15 |
| Melinda Lackey | Senior Vice President, Legal and Administration | Terminated | 2023-11-15 |
| Holger Weis | Chairman of the Board | Appointed | 2023-09-28 |
| James Huang | Chairman and member of the board of directors | Resigned | 2023-09-28 |
| Robert Hofmeister, Ph.D. | director | Appointed | 2023-03-30 |
Leadership
- Dale Curtis Hogue, Jr. CEO, Board Member
- Heidi Hagen CEO, Board Member
- Holger Weis CEO, Chairman, Board Member
- Kevin Boyle CEO, Board Member
- Timothy Cunningham CFO
- Kevin G. Lafond Chief Accounting Officer
- Douglas W. Pagán Board Member
- Elan Z. Ezickson Board Member
- J. Kevin Buchi Board Member
- Laurence J.N. Cooper Board Member
- Peter Harwin Board Member
- Robert Hofmeister, Ph.D. Board Member
- Robert Postma Board Member
- Scott Braunstein Board Member
Key facts
CIK
1107421
CUSIP
98973P309
13F (30d)
18 filings
11 filers
Visit website
Investor relations